Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
<p>Abstract</p> <p>Background</p> <p>Treatment of juvenile idiopathic arthritis (JIA) with disease-modifying antirheumatic drugs (DMARDs) may improve outcomes compared to conventional therapy (e.g., non-steroidal anti-inflammatory drugs, intra-articular corticosteroids)...
Saved in:
Main Authors: | Kemper Alex R (Author), Van Mater Heather A (Author), Coeytaux Remy R (Author), Williams John W (Author), Sanders Gillian D (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2012-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis
by: Cecilia Bava, et al.
Published: (2019) -
Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
by: Yinan Huang, et al.
Published: (2023) -
Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021) -
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020) -
Juvenile idiopathic arthritis
by: Krupa H Bhatt, et al.
Published: (2014)